TOULOUSE, France--(BUSINESS WIRE)--Jan 8, 2013--Regulatory News: Vexim (Paris:ALVXM) (FR0011072602 – ALVXM), a medical device company specializing in minimally invasive treatment of vertebral fractures, today announces the establishment of a new subsidiary, VEXIM SPINE S.L. in Spain (Barcelona) that will enable the company to accelerate the commercialization of the SpineJack® range in this territory.

“As announced at the time of our IPO in April 2012, we are accelerating our European development by establishing ourselves in Spain, the third largest kyphoplasty and vertebroplasty market in Europe. Following the recent openings of our German and Italian subsidiaries, we are expanding our European network in order to actively promote the SpineJack® to our prescribers and users: hospitals, clinics, surgeons and radiologists,” emphasizes Vincent Gardès, CEO of Vexim.

Vexim has already recruited Marta Farré Mateu as Sales Manager of Vexim Spain.

A key professional in kyphoplasty, she has contributed to the creation and development of this market during her 8 year experience as Field Sales Manager at Kyphon and as Sales Director and Key Account Manager at Medtronic. Marta Farré Mateu is 35 years old and lives in Barcelona.

Vexim has had a strong presence on the Spanish market since the clinical validation of the SpineJack® implant in 2008. Pr. David Noriega, Head of the Orthopedic Department at the University Hospital of Valladolid has been using the SpineJack® for more than 4 years and now comments: “With more than 300 treated fractures and monitoring of my first patients running for a bit more than 4 years, I can honestly say that the SpineJack® system is a very efficient alternative for minimally invasive treatment of vertebral compression fractures even in highly complex cases. This is a significant advance for surgeons but also for patients and healthcare systems. We all know that in these uncertain economic times, it is important to bring forward solutions that are increasingly efficient and that also enable the improvement of patients’ results and the reduction of treatment costs.” As in Germany, Italy and Switzerland, the commercial coverage in Spain will be carried out directly by a sales team that will intensify the relationships with referring physicians and opinion leaders.

About Vexim, the innovative back microsurgery specialist Based in Balma, near Toulouse (France), Vexim is a medical device specialist created in February. The Company has specialised in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital and Banexi Venture, and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a deformed or fractured vertebra and correcting the anatomy of the spinal column. The Company currently has 40 staff. It has its own sales teams in France, Germany, Italy, Spain and Switzerland, as well as distributors in Turkey, Argentina and South Africa. Vexim has been listed on NYSE Alternext Paris since 3 May 2012.

For further information, please go to SpineJack®, a revolutionary implant for treating Vertebral Compression Fractures The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out in a mini-invasive manner, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spinal columns, good medical-expense reimbursement systems in Europe and worldwide patent protection through to 2029.

Name : Vexim ISIN Code : FR0011072602 Ticker : ALVXM

CONTACT: Vexim Vincent Gardès, +33 5 61 48 48 38 CEO or NewCap.

Financial Communications and Investor Relations Dusan Oresansky / Emmanuel Huynh, +33 1 44 71 94 92 or Alize RP Press Relations Caroline Carmagnol, +33 6 64 18 99 59 or Christian Berg, +33 1 42 68 86 41 KEYWORD: EUROPE FRANCE INDUSTRY KEYWORD: SOURCE: Vexim Copyright Business Wire 2013 PUB: 01/08/2013 02:00 AM/DISC: 01/08/2013 02:00 AM